Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 9/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 9/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 8/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 8/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 8/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 8/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SCN1A | P35498 | 2/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 2/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levorphanol SCHEMBL5171217 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL24335 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL14326930 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL16310821 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL3495833 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL21095576 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL12232844 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL22791693 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levorphanol SCHEMBL22722062 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Dextrorphan SCHEMBL20535964 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7218 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260098013-A1 | Stereoisomer Conjugates of Dextrorphan | ZEVRA THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12539337-B2 | Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels | Molokanova, Elena (US) | 2026-02-03 | — | — | US | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2025202421-A1 | METHODS AND COMPOSITIONS | VRG 145 ZRT. (HU) | 2025-10-02 | — | — | WO | claimed |
| EP-3664791-B1 | EPLERENONE FOR PHENOTYPING OF CYP3A5 ENZYME ACTIVITY IN SALIVA SAMPLES | CU VENTURES INC (US) | 2025-10-01 | — | — | EP | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| WO-2025123137-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | 10763942 CANADA INC. (DBA. PURMINDS NEUROPHARMA) (CA) | 2025-06-19 | — | — | WO | claimed |
| US-20250195505-A1 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | BIOBINA LLC | 2025-06-19 | — | — | US | claimed |
| US-20250161296-A1 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | BIOBINA LLC | 2025-05-22 | — | — | US | claimed |
| US-5019579-A | Antitussive Agents | PRODOTTI FORMETI S.R.L. (IT) | 1991-05-28 | — | — | US | claimed |
| US-5013540-A | Using NMDA receptor antagonists to reduce damage due to laser treatment | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-05-07 | — | — | US | claimed |
| EP-0346445-A4 | DEXTRORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD. | FERKANY JOHN W (US) | 1990-03-28 | — | — | EP | claimed |
| EP-0359215-A1 | Oral pharmaceutical compositions containing dextrorphan salts | PRODOTTI FORMENTI S.r.l. (IT) | 1990-03-21 | — | — | EP | claimed |
| EP-0346445-A1 | DEXTRORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD | FERKANY, John W. (US) | 1989-12-20 | — | — | EP | claimed |
| WO-1989005642-A1 | DEXTRORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD | FERKANY JOHN W (US) | 1989-06-29 | — | — | WO | claimed |
| US-4806543-A | ADMINISTERING ENANTIOMER OF ANALGESIC OPIOD AGONIST OR ANTAGONIST COMPOUND | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1989-02-21 | — | — | US | claimed |
| EP-0270290-A2 | Method and compositions for reducing neurotoxic injury | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1988-06-08 | — | — | EP | claimed |
| EP-0219896-A1 | Pharmaceutical compositions on the basis of dextrorphan for intranasal application | PRODOTTI FORMENTI S.r.l. (IT) | 1987-04-29 | — | — | EP | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |